You are here: Industry Insights > gene therapy

News List

FDA approves third gene therapy for large B-cell lymphoma europeanpharmaceuticalreview
February 09, 2021
Breyanzi (lisocabtagene maraleucel) was approved on the 54 percent complete remission rate achieved in diffuse large B-cell lymphoma trials.
Vigene Plans Major Expansion in Maryland contractpharma
February 09, 2021
Vigene Biosciences, a global gene therapy development company, has unveiled plans to expand into a new facility in Montgomery County in Maryland to accommodate industry demand for its gene and cellular therapy products.
Lilly Completes $1B Acquisition of Prevail contractpharma
January 25, 2021
Eli Lilly and Company has successfully completed its $1.04 billion acquisition of Prevail Therapeutics Inc., adding a new modality for drug discovery and development at Lilly, and extending research efforts through the creation of a gene therapy ...
Cure Genetics Collaborates with Boehringer Ingelheim to Develop Novel AAV Vectors Enabling the Next-generation Liver-targeted Gene Therapy prnasia
January 19, 2021
Cure Genetics announced a collaboration with Boehringer Ingelheim to develop novel Adeno-Associated Virus (AAV) vectorsleveraging Cure Genetics' proprietary VELPTM platform to develop next-generation gene therapies.
Neurophth and AAVnerGene Enter Strategic AAV Capsids Partnership for Next-Generation Ophthalmic Gene Therapy prnasia
January 19, 2021
Neurophth Therapeutics, Inc. and AAVnerGene Inc. today announced a strategic partnership to provide Neurophth with worldwide rights to mutually select adeno-associated virus (AAV) capsids for the next generation ophthalmic gene therapy.
Rocket Pharmaceuticals announces buildout of R&D and manufacturing facility to support development of gene therapy pipeline pharmaceutical-business-review
January 14, 2021
Rocket Pharmaceuticals, a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, announces the Company’s plans for the buildout of its new Research and Development (R&D) and Chemistry ...
Biogen, ViGeneron Enter Gene Therapy Collaboration contractpharma
January 07, 2021
ViGeneron GmbH has announced a global collaboration and licensing agreement with Biogen Inc. to develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors to treat inherited eye diseases.
Gene Therapy Co. Selects ValGenesis' SaaS Platform contractpharma
January 07, 2021
ValGenesis, Inc., a provider of in Enterprise Validation Lifecycle Management Systems (VLMS), was selected by a gene therapy company to digitize its corporate validation process.
Neurogene closes $115m series B financing pharmaceutical-business-review
December 21, 2020
Neurogene, a company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the completion of a $115m Series B financing.
Passage Bio Invests in Gene Therapy Manufacturing R&D Site contractpharma
December 18, 2020
In combination with dedicated cGMP suite at Catalent, the new lab creates foundation for integrated AAV gene therapy manufacturing.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 20 21 Next page